Get the Stockscreener App
4.14
0.72%
-0.03
Pre-market:
4.06
-0.08
-1.93%
Cytek Biosciences Inc stock is traded at $4.14, with a volume of 838.67K.
It is down -0.72% in the last 24 hours and down -20.69% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$4.17
Open:
$4.17
24h Volume:
838.67K
Relative Volume:
1.19
Market Cap:
$530.32M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-46.00
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
-7.17%
1M Performance:
-20.69%
6M Performance:
-15.68%
1Y Performance:
-38.58%
1-Day Range:
$4.05
$4.205
1-Week Range:
$4.05
$4.61
52-Week Range:
$4.05
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.14 | 530.32M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences stock hits 52-week low at $4.19 amid market challenges - Investing.com Australia
Cytek Biosciences, Inc. (CTKB): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call Transcript - MSN
Cytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Principal Financial Group Inc. - Defense World
Cytek Biosciences (NASDAQ:CTKB) Price Target Cut to $8.00 by Analysts at Piper Sandler - Defense World
Cytek Biosciences Reports Mixed Earnings Amid Growth and Challenges - TipRanks
Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low – Here’s Why - Defense World
Cytek Biosciences stock hits 52-week low at $4.6 amid market challenges - Investing.com Australia
Is There An Opportunity With Cytek Biosciences, Inc.'s (NASDAQ:CTKB) 22% Undervaluation? - Yahoo Finance
Cytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cytek Biosciences stock hits 52-week low at $4.6 amid market challenges By Investing.com - Investing.com South Africa
Cytek Biosciences, Inc. SEC 10-K Report - TradingView
Cytek Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cytek Biosciences Reports Growth and Strategic Expansion - TipRanks
Cytek Biosciences earnings beat by $0.01, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Cytek Biosciences Q4 2024 results miss forecasts By Investing.com - Investing.com South Africa
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates - Yahoo Finance
Earnings call transcript: Cytek Biosciences Q4 2024 results miss forecasts - Investing.com
Cytek Biosciences reports Q4 revenue $57.48M, consensus $59.38M - TipRanks
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook - GlobeNewswire
Cytek's Earnings Show Profitability Surge: Net Loss Halved While Revenue Climbs Just 4% - StockTitan
Cytek Biosciences (CTKB) to Release Quarterly Earnings on Thursday - MarketBeat
(CTKB) Proactive Strategies - Stock Traders Daily
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update - MarketBeat
Cytek Biosciences (CTKB) Projected to Post Quarterly Earnings on Thursday - Defense World
Cytek Biosciences (NASDAQ:CTKB) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Prenetics Global (NASDAQ:PRE) and Cytek Biosciences (NASDAQ:CTKB) Head to Head Analysis - Defense World
Cytek Biosciences to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
Cytek Biosciences Earnings Alert: Key Q4 and Full Year 2024 Results Coming February 27 - StockTitan
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Cytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume – Here’s What Happened - Defense World
Keeping an Eye on Cytek BioSciences Inc (CTKB) After Insider Trading Activity - Knox Daily
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4%Should You Sell? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%What's Next? - MarketBeat
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Strategic Investor Access: Cytek Sets Ambitious 4-Conference Roadshow for Early 2025 - StockTitan
Pacer Advisors Inc. Buys Shares of 30,155 Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4% – Should You Sell? - Armenian Reporter
Market Insights: Cytek BioSciences Inc (CTKB)’s Notable Gain of 4.66, Closing at 5.39 - The Dwinnex
Cytek Biosciences (NASDAQ:CTKB) Shares Gap DownHere's Why - MarketBeat
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytek Biosciences Inc Stock (CTKB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yan Ming | CHIEF TECHNOLOGY OFFICER |
Apr 09 '24 |
Sale |
7.00 |
1,900 |
13,304 |
6,008,502 |
| Yan Ming | CHIEF TECHNOLOGY OFFICER |
Mar 18 '24 |
Sale |
6.77 |
20,000 |
135,400 |
6,030,402 |
| Yan Ming | CHIEF TECHNOLOGY OFFICER |
Mar 19 '24 |
Sale |
6.71 |
20,000 |
134,200 |
6,010,402 |
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):